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Abstract
Background: The historical Japanese influenza vaccination program targeted at schoolchildren provides a unique
opportunity to evaluate the indirect benefits of vaccinating high-transmitter groups to mitigate disease burden among
seniors. Here we characterize the indirect mortality benefits of vaccinating schoolchildren based on data from Japan and the
US.
Methods: We compared age-specific influenza-related excess mortality rates in Japanese seniors aged $65 years during the
schoolchildren vaccination program (1978–1994) and after the program was discontinued (1995–2006). Indirect vaccine
benefits were adjusted for demographic changes, socioeconomics and dominant influenza subtype; US mortality data were
used as a control.
Results: We estimate that the schoolchildren vaccination program conferred a 36% adjusted mortality reduction among
Japanese seniors (95%CI: 17–51%), corresponding to ,1,000 senior deaths averted by vaccination annually (95%CI: 400–
1,800). In contrast, influenza-related mortality did not change among US seniors, despite increasing vaccine coverage in this
population.
Conclusions: The Japanese schoolchildren vaccination program was associated with substantial indirect mortality benefits
in seniors.
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Introduction
Despite current approaches to prevention and control, seasonal
influenza remains a significant cause of morbidity and mortality
worldwide. While the elderly have the highest mortality rates of
all age groups, school-aged children are the most important
sources of community-wide transmission [1]. Vaccination is
currently the most effective means of preventing seasonal
influenza. Until recently, the seasonal vaccination strategy in
the US targeted persons at risk for serious complications
including seniors aged $65 years, individuals with chronic
conditions, children aged 6–23 months, and pregnant women [2].
Vaccine recommendations have gradually been expanded to
include all persons $6 months, but vaccination coverage among
school-aged children in the US has remained modest [3,4].
Analysis of US national vital statistics revealed that increasing
vaccination coverage in seniors from 1980 to 2001 did not
correlate with a decline in influenza-related mortality [5];
influenza-related hospitalization rates increased steadily in
persons aged $50 years during this time period [6]. These
findings suggest that the strategy of vaccinating only ‘‘high risk’’
populations may not be sufficient to decrease influenza
transmission and severe burden at the population level, in part
due to the weak immune response of seniors to vaccination [7].
A complementary, albeit debated, vaccination strategy specif-
ically targets schoolchildren to reduce community-wide transmis-
sion of seasonal influenza. School-based trials and observational
studies in the US and Russia suggest that the vaccination of
schoolchildren can reduce influenza-related morbidity and
mortality among non-immunized contacts and the elderly [8–
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14]. In a recent cluster-randomized controlled trial, immunization
of ,80% of schoolchildren conferred a 61% indirect protection
against influenza infection to unvaccinated individuals [15]. While
promising, these studies were conducted in small or selected
populations and do not necessarily provide sufficient evidence to
change vaccination policies [1]. Further evaluation of the
population-level effects of different vaccination strategies is
warranted to improve influenza control programs.
The Japanese experience offers a unique opportunity to
examine the population-level benefits of vaccinating schoolchil-
dren. From 1977 to 1987, the Japanese schoolchildren vaccina-
tion program achieved between 50 and 85% annual coverage in
children aged 3 to 15 years. The program was officially
discontinued in 1994, when the priority groups for vaccination
switched to seniors aged $65 years and those aged 60–64 years
with high-risk conditions [16–21] (Table S1). A previous study of
mortality trends by Reichert et al. showed that the Japanese
schoolchildren vaccination program was associated with a
decrease in the overall number of influenza-related excess deaths
and that excess deaths increased once the program was
discontinued [16]. Unfortunately, the study suffered from
methodological issues related to the estimation of influenza
disease burden, and did not adjust for variation in circulating
strains and rapid socio-economic and demographic changes
following World War II [22–24]. Further, Reichert et al. could
not quantify the indirect benefits of schoolchildren vaccination on
mortality among seniors due to lack of age-specific data [16]. In
the present study, we carefully re-examine the Japanese
vaccination strategy by analyzing detailed age-specific mortality
and virus surveillance data, and address previous methodological
criticisms. More importantly, we develop a statistical approach to
quantify the indirect effects of schoolchildren vaccination on
influenza-related mortality in seniors, using data from the US as a
control.
Methods
A detailed description of the data sources and analytic approach
is given in Information S1 and summarized below.
Mortality data and excess mortality approach
We compiled monthly pneumonia and influenza (P&I) deaths
and population estimates for individuals $65 yrs during 1978–
2006 from the Japanese Ministry of Health, Labor and Welfare
and the US National Center for Health Statistics (Table S2). As in
previous studies, we concentrated on trends in P&I mortality rates,
a specific indicator of influenza-related mortality [25,17]. We
focused on the 1978–2006 time period to obtain reliable
information on vaccine coverage ([17] and Table S1) and to
avoid the period of adaptation following the 1968 influenza A/
H3N2 pandemic, during which mortality in Japan and the US
declined steeply even in the absence of vaccination [16]. Mortality
data were stratified by five senior age groups (65–69, 70–74, 75–
79, 80–84, 85–89 years) to allow careful adjustment for changing
post-war demographics. Data on dominant influenza subtypes
circulating in Japan and the US during the study period were
obtained from [5,17].
To estimate seasonal influenza-related mortality rates, we
applied Serfling cyclical regression models to monthly P&I death
rates for each country and age-group, as in [5,26]. These models
provide seasonal baseline levels of expected mortality in the
absence of influenza virus circulation. Mortality observed in excess
of the baseline during influenza-epidemic months is attributed to
influenza and termed ‘‘seasonal excess mortality’’.
Estimating excess mortality reduction among seniors
To account for long-term changes in mortality unrelated to
influenza and for baseline differences between Japan and the US,
we standardized winter-seasonal excess P&I mortality rates for
changes in population structure and summer mortality rates
(Information S1). This approach has been used in the past to
adjust for differences in socioeconomic status and access to
healthcare between high and middle-income countries [27]. We
chose the US summer P&I mortality rate and population structure
in 2000 as a reference.
To quantify the indirect benefits of the Japanese vaccination
program, we assessed differences in crude and adjusted excess P&I
mortality rates during the schoolchildren vaccination period
(1978–1994) and the period immediately after the program was
discontinued (1995–2006). We modeled age-stratified seasonal
excess death rates using multivariate negative binomial regression,
using a log-link with a dummy indicator for time period, adjusting
for age and dominant virus subtype. A formal description of the
model used and model diagnostics are provided in the Fig. S3,
Table S8. We checked that interaction terms between the time
period and age variables were not significant in the model. We also
compared influenza-related mortality trends in Japan with those in
the US using the same methodology, utilizing the US experience
as a concurrent control that did not implement the vaccination of
schoolchildren.
Results
Influenza-related mortality trends in Japanese and
American seniors
Monthly time series of P&I mortality rates in Japanese and
American elderly, aged 65–89 years, reveals a series of peaks in
November–April during 1978–2006 (Fig. 1). On average, peaks of
P&I mortality in Japan reached magnitudes ,50% larger than
those in the US. Influenza A/H3N2 was dominant in 17 of the 29
seasons studied in both countries.
To examine long-term trends in influenza-related mortality we
calculated excess P&I mortality rates for 29 winter seasons, 1977/
1978 to 2005/2006 (Fig. 2, Table S3). On average, over the entire
period studied, crude excess mortality rates were higher in Japan
than in the US (19 v. 16 per 100000, respectively), but this patterns
reversed after adjustment for population demographics and socio-
economic trends (Table 1). Indeed, adjustment for between-
country differences in socio-economic conditions, using summer
mortality rates experienced in the US in 2000 as a reference,
resulted in a ,50% reduction in Japanese winter-seasonal excess
P&I mortality rates. In both countries, excess mortality rates
increased sharply with age (Fig. 3A & 3C, Tables S4) and were 2.1
to 2.5- fold higher during A/H3N2-dominant seasons than those
dominated by influenza A/H1N1 or B (Table S3). A sharp
elevation in excess mortality was observed in the US and Japan
during 1997–2000, a period concurrent with four sequential A/
H3N2-dominated seasons (Fig. 2).
Estimating the indirect mortality benefits of the Japanese
schoolchildren vaccination program
To evaluate the effectiveness of the Japanese schoolchildren
vaccination program we compared excess influenza-related
mortality rates when the program was in place (1978–1994) with
those in the decade after the program was discontinued (1995–
2006). In Japan, average crude and adjusted excess P&I mortality
rates among seniors increased by 93 and 113%, respectively,
during the post-schoolchildren vaccination program period
(P,0.04, Table 1). In addition, excess mortality rates increased
Vaccination and Excess Mortality, US and Japan
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by 26 to 114% across the 5 senior age subgroups after the program
was terminated (Fig. 3A & 3B, Tables S4). Interestingly, the
increase in excess mortality rates was more pronounced in older
age groups (P,0.05 for adjusted mortality rates among 70–89 year
olds).
To check that the increase in excess P&I mortality in Japan
after 1994 was specific to the discontinuation of the schoolchil-
dren vaccination program, we used trends in excess P&I
mortality in the US over the same time period as a control. In
contrast to Japan, there was no difference in excess mortality
rates before and after 1994, in any of the US senior age groups
(Table 1, Fig. 3C–D). In addition, adjusted excess mortality
rates in Japan were significantly lower than those in the US
during the Japanese schoolchildren vaccination program
(P = 0.001) and subsequently became similar to those in the
US (P = 0.18, Table S5).
To further control for increased circulation of the influenza A/
H3N2 subtype after the Japanese schoolchildren vaccination
program was discontinued, we fit negative binomial models to
seasonal excess mortality rates, with time period, dominant
influenza subtype, and the five age groups as covariates (Table 2).
In Japan, the relative risk of adjusted excess mortality in seniors
was 0.64 during the vaccination program (95% CI: 0.49–0.83),
corresponding to a 36% reduction in excess mortality through
indirect protection (95% CI 17–51%). These vaccination benefits
represent 992 adjusted excess deaths averted per season among
seniors in Japan (95% CI: 355–1,825) or 7.5 deaths averted per
100,000 (95% CI: 2.8–14.4 per 100,000). The estimated benefits
were lower in the unadjusted data (Table 2). In contrast to Japan,
the same modeling approach applied to the US data revealed no
significant difference in the risk of excess mortality between the
two periods (Table 2).
To ensure that our findings were not simply the byproduct of
the particular time periods chosen, we repeated our analysis using
different time periods for trend comparisons. For instance, we
compared the last ten influenza seasons of the schoolchildren
vaccination program (1983–1994) with the first ten seasons after
the program was discontinued (1995–2006). The reductions in
excess P&I mortality rates associated with the schoolchildren
vaccination program were even more pronounced when we
considered these shorter periods (Table S7).
Finally, as a sensitivity analysis, we compared influenza
vaccination strategies in Japan and the US by including excess
mortality rates from both countries in the same model, allowing
direct between-country comparisons (Table S6). This model
confirmed that Japanese seniors were at lower risk of adjusted
excess P&I death during the schoolchildren vaccination
program compared to when the program was discontinued,
and produced similar mortality reductions as before (36%, 95%
CI: 17–50%). Interestingly, however, Japanese seniors remained
at lower risk of death than US seniors during the entire study
period (Table S6).
Figure 1. Pneumonia and influenza (P&I) mortality rates among the Japanese (A) and US (B) elderly, aged 65–89 years, Jan. 1977–
Dec. 2006. Expected mortality rates in the absence of influenza virus circulation are shown in black, as determined by the Serfling seasonal baseline
approach. Influenza epidemic months are highlighted in grey.
doi:10.1371/journal.pone.0026282.g001
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Discussion
To evaluate the indirect mortality benefits of the Japanese
schoolchildren vaccination program, we studied seasonal influen-
za-related excess mortality rates among Japanese and American
seniors from 1978 to 2006. We found that crude excess P&I
mortality rates in Japanese seniors increased by 93% after the
schoolchildren vaccination program was discontinued in 1994. A
large fraction of this increase was due to more frequent circulation
of the severe influenza A/H3N2 virus subtype in recent years.
After controlling for circulating subtype, trends in population
demographics and baseline risk of death, we estimated that the
schoolchildren vaccination program conferred a 36% protective
benefit against influenza-related mortality to Japanese seniors
(95% CI:17–51%). On average, we estimate that this program was
associated with 992 excess P&I deaths averted per season (95% CI:
355–1,825). In addition to this statistical analysis, we developed an
age-structured transmission model to estimate the indirect
mortality benefits of schoolchildren vaccination (Information S1).
The model predicted a 26–52% reduction in influenza-related
mortality amongst senior populations, consistent with our
statistical findings (Figs. S1–2).
To control for changes in the severity of circulating influenza
viruses, we estimated trends in influenza-related mortality in the
US, where influenza vaccination was targeted to high-risk groups
and coverage among seniors has gradually increased to ,65%.
We did not find significant changes in influenza-related mortality
rates among US seniors during the study period (1978–2006),
consistent with previous work [16].
In 2001, Reichert et al. reported that the Japanese schoolchil-
dren vaccination program prevented between 10,000 and 12,000
excess P&I deaths per season in the entire population, but the
authors did not analyze mortality data specific to seniors [16].
Our estimate of 992 excess P&I deaths (95% CI: 335–1,825)
averted among seniors is substantially lower. Reichert et al.
estimated mortality reductions by comparing excess P&I
mortality rates in 1990 to those in the 1960 s. Notably,
influenza-related excess mortality rates in the 1950 s–60 s were
declining sharply in all countries due to socio-economic changes.
Excess mortality rates also declined during the years immediately
following the 1968 A/H3N2 pandemic, likely due to the
population-wide acquisition of natural immunity to these viruses
over time (rather than to vaccination) [5,28]. In addition, this
study and others have shown that excess mortality estimates are
very sensitive to the frequency of A/H3N2 virus circulation,
which was not controlled for in the Reichert et al. study [16].
Therefore, we believe our evaluation of the schoolchildren
vaccination program using mortality data specific to seniors,
Figure 2. Seasonal excess pneumonia and influenza (P&I) mortality rates among the Japanese (A) and the US elderly (B), aged 65–
89 years, 1977–78 to 2005–06 seasons. Squares represent seasons dominated by influenza A/H3N2 viruses; circles represent seasons dominated
by influenza A/H1N1 or B. Blue symbols represent crude excess mortality estimates; red symbols represent excess mortality estimates adjusted for
population aging and trends in baseline mortality risk. The blue and red lines represent 5-yr moving averages of the crude and adjusted seasonal
excess mortality rates, respectively. Grey bars in (A) represent the number of vaccine doses distributed per influenza season in Japan; grey bars in (B)
represent the influenza vaccine coverage among the US non-institutionalized elderly aged $65.
doi:10.1371/journal.pone.0026282.g002
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and including recent years for comparison, is more prudent and
allows adjustment for important confounders.
Our results can also be compared to those of a recent
Canadian cluster-randomized controlled trial, in which immuni-
zation of ,80% of schoolchildren conferred 61% indirect
protection against clinical influenza infection to unvaccinated
individuals (95% CI: 8–83%) [15]. Our analysis suggests a lower
indirect mortality benefit of 36% (95% CI: 17–51%), although
the confidence intervals of the two studies are large and overlap.
Our study’s lower point estimate could be explained by lower
vaccination rates among Japanese schoolchildren, or lower
efficacy of historical vaccines [18,19,21]. We note that our age-
structured transmission model corresponds well with the
Canadian findings, predicting a ,60% reduction in influenza-
related mortality among seniors at high vaccine coverage (Fig.
S2). Further research should focus on combining epidemiological
data with mathematical transmission models to evaluate different
vaccination strategies.
Several limitations of our study should be mentioned. We
concentrated on P&I mortality, despite the fact that the impact of
influenza is not limited to solely P&I [29]. The Japanese
schoolchildren vaccination program was associated with a non-
significant reduction in excess all-cause mortality in seniors (not
shown), which could be explained by a lack of specificity and
unaccounted baseline time trends [5,25]. Although it would have
been interesting to investigate trends in other causes of death
traditionally linked to influenza, such as respiratory and cardiac
diseases, these data were not available to us. Additionally, our
study was ecological and prone to confounders, which is why we
introduced the US comparison as a control. Furthermore, we
adjusted for the circulation of more virulent A/H3N2 viruses,
accounted for population aging by studying age-specific mortality
rates and used sensitivity analyses to explore the robustness of our
findings. We also supplemented our data on vaccine doses
distributed with age-specific vaccine coverage data for selected
years [18,19,21]. Finally, we used mortality data from summer
Figure 3. Crude (left panels) and adjusted (right panels) excess pneumonia & influenza (P&I) seasonal mortality rates by age group
and time period in Japan (top) and the US (bottom). Rates were adjusted for time trends in the baseline risk of mortality. Asterisks indicate
statistically significant differences between the two time periods using Wilcoxon’s Rank Sum Test (P,0.05).
doi:10.1371/journal.pone.0026282.g003
Table 1. Average excess P&I mortality rates per 100,000 in Japanese and US seniors aged 65–89 yrs, 1978–2006.
1978–2006
Avg. (SD)
1978–1994
Avg. (SD)
1995–2006
Avg. (SD) % change between time periods P-value
Japan Excess P&I 19.18 (15.9) 13.85 (11.0) 26.73 (19.0) 93% 0.034
Japan Adjusted Excess P&I 10.00 (8.7) 6.82 (5.8) 14.51 (10.3) 113% 0.027
USA Excess P&I 16.39 (7.7) 15.26 (8.3) 17.99 (6.9) 18% 0.445
USA Adjusted Excess P&I 16.94 (8.5) 16.25 (9.5) 17.91 (7.0) 10% 0.527
Standard deviations are tabulated in parentheses. Percent changes were calculated as the mean mortality rate in 1995–2006 (the period after discontinuation of the
Japanese schoolchildren vaccination program) minus that in 1978–1994 (the schoolchildren vaccination program period in Japan), divided by the mean mortality rate in
1978–1994. P-values were determined using Wilcoxon’s Rank Sum Test. Adjusted estimates were standardized to the US population structure of 2000 and corrected for
time trends in the baseline risk of mortality (see Methods).
doi:10.1371/journal.pone.0026282.t001
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periods, free of the effect of influenza, to adjust for time trends in
the background risk of death among seniors in 1978–2006 due to
differences in access to care, underlying co-morbidities or other
causes. Patterns identified in adjusted excess mortality estimates
were always in the same direction as those identified in crude
mortality estimates.
We considered two competing explanations for the increase in
excess influenza-related mortality observed in Japanese seniors
after the schoolchildren vaccination program was discontinued:
the growing impact of nursing homes and antiviral treatment.
While the number of ‘‘Nursing Homes for the Elderly’’ increased 5
fold between 1980 and 2006 in Japan, the percentage of three-
generation households decreased from 16.2 to 9.1% [30,31].
However, the overall proportion of elderly persons living in
nursing facilities remained low throughout the study period in
Japan and could not account for the substantial increases seen in
influenza-related mortality rates in recent years.
Oseltamivir use has increased substantially in Japan since
2003 in all age groups, making Japan the country with the
highest annual level of oseltamivir use per capita, comprising
.70% of the world’s consumption in 2009 [32,33]. The decline
in influenza-related mortality in the Japanese elderly observed
after 2000 may be due in part to the routine use of oseltamivir
and in part to increasing vaccination rates amongst the elderly,
other high-risk groups, and children aged 6–13 years (Fig. 2,
Table S1). While it is too soon to precisely evaluate to effect of
oseltamivir use on influenza-related mortality in the Japanese
population, high oseltamivir usage was limited to the last 3 years
of our study and would only bias our analyses towards null
hypotheses.
In conclusion, numerous studies have reported that school-
aged children have high influenza attack rates and play an
important role in the transmission of influenza within schools,
families and communities [34–38]. Importantly, children respond
well to vaccination and vaccinating this age-group is cost-
effective, regardless of indirect benefits to unvaccinated contacts
[39–41]. Here, we have shown that the Japanese schoolchildren
vaccination program was associated with significant reductions in
influenza-related excess P&I mortality among the Japanese
elderly. Our estimates of indirect vaccination benefits are
conservative because they focus on P&I mortality, a fraction of
the total mortality burden of influenza and because the Japanese
population has not entirely escaped influenza vaccination or
antiviral treatment since the schoolchildren vaccination program
was discontinued. Our findings fit well with an accumulating
body of theoretical and experimental evidence suggesting that
high vaccination coverage of children can contribute to
reductions in morbidity and mortality among non-immunized
community members [42–44].
While the societal structure of Japan is markedly different from
that of the US, we believe that our findings can extend to the US
population for several reasons. First, several community-scale
studies in the US have indicated that vaccinating schoolchildren
against influenza confers herd immunity in unvaccinated
community members [8–10,15]. Second, the introduction of
several pediatric vaccines has produced substantial herd protec-
tive effects on the population level, most notably the pneumo-
coccal vaccine [34]. In particular, the US-introduction of a
vaccine targeting seven types of pneumococcal disease in young
children in 2000 has substantially reduced the rates of carriage
and invasive disease amongst people aged .50 years [44]. Our
findings support vaccination of school-aged children, a group
included in the most recent ACIP recommendations, which
encourage yearly seasonal influenza vaccination for all persons
aged $6 months in the US [3]. While seasonal influenza vaccine
coverage remained low in US children aged 6 months – 17 years
during the 2008–2009 epidemic season, they reached ,44%
towards the end of 2009 [45,46]. It will be interesting to compare
influenza-related disease trends in the US with those in other
countries as vaccine coverage continues to increase in pediatric
populations.
Supporting Information
Figure S1 Schematic of the compartmental influenza
transmission model used to evaluate observed trends in
Japanese excess mortality. Note that the actual model is
structured into 15 age groups.
(DOC)
Figure S2 Reduction in influenza-related mortality
rates among Japanese elderly, results from an age-
structured model of influenza transmission. (A) Reduc-
tion in influenza-related mortality rates amongst the elderly
(blue-red), as a function of influenza vaccine coverage in
schoolchildren (y-axis) and effective reproduction number, Re,
(x-axis) as predicted by our influenza transmission model. Vac-
cine efficacy is set at 42% (B) Same as in A) but with varying
vaccine efficacy (y-axis); vaccination coverage in schoolchildren
is held at 70%.
(DOC)
Figure S3 Negative binomial model diagnostics. Panel A
depicts the model residuals v. predicted values, while panel B
depicts the observed data v. the model fitted values (y = x line
present for reference). See Table 2 of the main text for model
results and interpretation; see Eq. 2 above for a full description of
the statistical model.
(DOC)
Table S1 Age-specific influenza vaccination rates, Ja-
pan, 2000–2006.
(DOC)
Table 2. Relative risks of excess P&I death among seniors aged 65–89 in 1995–2006 compared to 1978–1994 in Japan and the US,
controlling for influenza subtype dominance, population aging, and trends in baseline risk of mortality.
Model Outcome
Adjusted RR (1978–1994
v. 1995–2006)
Adjusted Protective Effectiveness
of the Vaccination Program (%)
Number of Deaths Averted per Season due to
the Schoolchildren Vaccination Program
Japan Adjusted Excess P&I: 0.64 (0.49–0.83) 35.90 (16.67–50.74) 992 (355–1825)
USA Adjusted Excess P&I: 1.04 (0.87–1.24) 24.16 (223.46–13.04) _
The period 1978–1994 corresponds to the schoolchildren vaccination program in Japan, which was discontinued after 1994. Vaccine protective effectiveness estimates
were calculated as (1-1/RR)6100.
doi:10.1371/journal.pone.0026282.t002
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Table S2 Underlying cause of death codes used to
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Classification of diseases).
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Table S3 Crude and adjusted influenza-related excess
mortality rates per 100,000 among Japanese and Amer-
ican seniors aged 65–89 yrs, and dominant influenza
subtypes in circulation, 1978–2006. Adjusted mortality rates,
standardized to the US population structure of 2000 and adjusted
for time trends in the baseline risk of mortality, are displayed in
parentheses.
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Table S4 Comparison of crude and adjusted excess P&I
mortality rates per 100,000 among Japanese and US
seniors in 1978–1994 with those in 1995–2006. Adjusted
rates take into account time trends in baseline mortality risk.
Percent changes were calculated as the mean mortality rate in
1995–2006 minus that in 1978–1994, divided by the mean
mortality rate in 1978–1994. P-values were determined using
Wilcoxon’s Rank Sum Test.
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Table S5 Comparison of adjusted excess P&I mortality
rates per 100,000 between Japanese and American
seniors, aged 65–89. Standard deviations are tabulated in
parentheses. P-values were determined using Wilcoxon’s Rank
Sum Test.
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Table S6 Sensitivity analysis including US and Japan
mortality data in the same model. We modeled age-
adjusted excess P&I estimates in Japan and the USA using
multivariate negative binomial regression. Adjusted excess P&I
estimates were standardized to the US summer mortality rate of
2000. We evaluated three different vaccination periods (Japan
1978–1994, schoolchildren vaccination; Japan 1995–2006, mixed
vaccination; USA 1978–2006, elderly vaccination), adjusting for
age, time trends in baseline mortality risk, and A/H3N2 subtype
dominance.
(DOC)
Table S7 Sensitivity analysis of time periods considered
in mortality trend comparisons. Comparison of crude and
adjusted excess P&I mortality rates among Japanese and US
seniors in 1983–1994 with those in 1995–2006. Adjusted rates take
into account time trends in baseline mortality risk. Percent
changes were calculated as the mean mortality rate in 1995–
2006 minus that in 1983–1994, divided by the mean mortality rate
in 1983–1994. P-values were determined using Wilcoxon’s Rank
Sum Test.
(DOC)
Table S8 Parameter estimates and standard errors of
the negative binomial model used to estimate the
reduction in influenza-related mortality among Japa-
nese seniors during the vaccination of schoolchildren
time period (1978–1994). Note that the 65–69 year old age
group is used as a reference, and all model terms are statistically
significant (P,0.05). See Eq. 2 above for a full description of the
statistical model.
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